![]() |
Name |
1H-Indene-1-methanol, acetate
|
Molecular Formula | C12H12O2 | |
IUPAC Name* |
1H-inden-1-ylmethyl acetate
|
|
SMILES |
CC(=O)OCC1C=CC2=CC=CC=C12
|
|
InChI |
InChI=1S/C12H12O2/c1-9(13)14-8-11-7-6-10-4-2-3-5-12(10)11/h2-7,11H,8H2,1H3
|
|
InChIKey |
PLQXNZFNLFQNIV-UHFFFAOYSA-N
|
|
Synonyms |
1H-Indene-1-methanol acetate; 1H-Indene-1-methanol, acetate; SCHEMBL8066098; 1H-Inden-1-ylmethyl acetate #; 51926-98-8
|
|
CAS | NA | |
PubChem CID | 581746 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 188.22 | ALogp: | 2.4 |
HBD: | 0 | HBA: | 2 |
Rotatable Bonds: | 3 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 26.3 | Aromatic Rings: | 2 |
Heavy Atoms: | 14 | QED Weighted: | 0.666 |
Caco-2 Permeability: | -4.597 | MDCK Permeability: | 0.00003390 |
Pgp-inhibitor: | 0.229 | Pgp-substrate: | 0.002 |
Human Intestinal Absorption (HIA): | 0.006 | 20% Bioavailability (F20%): | 0.036 |
30% Bioavailability (F30%): | 0.009 |
Blood-Brain-Barrier Penetration (BBB): | 0.999 | Plasma Protein Binding (PPB): | 83.57% |
Volume Distribution (VD): | 1.249 | Fu: | 23.21% |
CYP1A2-inhibitor: | 0.74 | CYP1A2-substrate: | 0.164 |
CYP2C19-inhibitor: | 0.485 | CYP2C19-substrate: | 0.84 |
CYP2C9-inhibitor: | 0.105 | CYP2C9-substrate: | 0.454 |
CYP2D6-inhibitor: | 0.084 | CYP2D6-substrate: | 0.815 |
CYP3A4-inhibitor: | 0.147 | CYP3A4-substrate: | 0.555 |
Clearance (CL): | 4.149 | Half-life (T1/2): | 0.684 |
hERG Blockers: | 0.063 | Human Hepatotoxicity (H-HT): | 0.27 |
Drug-inuced Liver Injury (DILI): | 0.128 | AMES Toxicity: | 0.956 |
Rat Oral Acute Toxicity: | 0.33 | Maximum Recommended Daily Dose: | 0.884 |
Skin Sensitization: | 0.805 | Carcinogencity: | 0.733 |
Eye Corrosion: | 0.008 | Eye Irritation: | 0.36 |
Respiratory Toxicity: | 0.55 |